Valuation: BioNTech SE

Market Cap 2.08TCr 2.38TCr 1.92TCr 1.78TCr 3.37TCr 2,25600Cr 3.43TCr 23TCr 8.94TCr 1,11300Cr 8.92TCr 8.73TCr 3,84900Cr P/E 2026 *
-18.7x
P/E 2027 * -18.4x
Enterprise Value 995.1Cr 1.14TCr 917.08Cr 850.02Cr 1.61TCr 1,07900Cr 1.64TCr 11TCr 4.28TCr 53TCr 4.27TCr 4.18TCr 1,84100Cr EV / Sales 2026 *
4.59x
EV / Sales 2027 * 5.17x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 week-0.61%
Current month+0.61%
1 month+6.98%
3 months+3.54%
6 months-2.09%
Current year+0.86%
1 week 81
Extreme 81
86.15
1 month 73.2
Extreme 73.2
86.15
3 years 68.35
Extreme 68.35
124.7
5 years 68.35
Extreme 68.35
397
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.79%-0.61%-12.81%-15.81% 2.38TCr
-0.10%+0.10%+74.33%+133.26% 5.77TCr
-3.80%-6.24%+67.04%+86.36% 5.47TCr
+1.52%+6.57%+17.20%+472.13% 2.42TCr
-2.70%+4.25%+40.38%-3.72% 1.98TCr
+3.78%+5.65%+44.99%-26.23% 1.71TCr
+3.46%+17.72%+206.66%+364.07% 1.68TCr
-1.81%+18.00%+41.99% - 1.56TCr
+2.32%+4.42%+28.66%+194.23% 1.4TCr
+3.99%+2.52%+90.36%+151.21% 1.22TCr
Average +0.76%+5.64%+59.88%+150.61% 2.58TCr
Weighted average by Cap. -0.22%+3.56%+59.66%+139.82%

Financials

2026 *2027 *
Net sales 216.59Cr 247.5Cr 199.61Cr 185.01Cr 351.21Cr 23TCr 356.87Cr 2.39TCr 930.77Cr 12TCr 929.18Cr 909.06Cr 40TCr 223.05Cr 254.89Cr 205.56Cr 190.53Cr 361.69Cr 24TCr 367.52Cr 2.46TCr 958.56Cr 12TCr 956.93Cr 936.21Cr 41TCr
Net income -105.09Cr -120.08Cr -97Cr -90Cr -170.4Cr -11TCr -173.15Cr -1.16TCr -451.6Cr -5.62TCr -450.83Cr -441.07Cr -19TCr -116.54Cr -133.17Cr -107.4Cr -100Cr -188.97Cr -13TCr -192.02Cr -1.29TCr -500.81Cr -6.24TCr -499.96Cr -489.13Cr -22TCr
Net Debt -1.09TCr -1.24TCr -1TCr -927.01Cr -1.76TCr -1,17700Cr -1.79TCr -12TCr -4.66TCr -58TCr -4.66TCr -4.55TCr -2,00800Cr -928.08Cr -1.06TCr -855.31Cr -792.77Cr -1.5TCr -1,00700Cr -1.53TCr -10TCr -3.99TCr -50TCr -3.98TCr -3.9TCr -1,71700Cr
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
-
Date Price Change
08/26/08 82.65 +0.79%
06/26/06 €82.00 -2.61%
03/26/03 €84.20 -1.64%
02/26/02 €85.60 +3.32%
01/26/01 €82.85 +1.66%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
82.26EUR
Average target price
106.82EUR
Spread / Average Target
+29.85%

Quarterly revenue - Rate of surprise